Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
97 studies found for:    Open Studies | niaid
Show Display Options
Rank Status Study
1 Not yet recruiting Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Condition: HIV Infections
Interventions: Drug: Oral CAB;   Drug: Oral TDF/FTC;   Drug: Placebo for oral CAB;   Drug: Placebo for oral TDF/FTC;   Drug: CAB LA;   Drug: Placebo for CAB LA
2 Not yet recruiting Targeted Microbiome Transplant in Atopic Dermatitis
Condition: Atopic Dermatitis (AD)
Interventions: Biological: TMT Lotion;   Drug: Placebo Lotion
3 Not yet recruiting Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
Conditions: Tuberculosis;   HIV Infections
Interventions: Drug: Delamanid;   Drug: Optimized multidrug background regimen (OBR) for children with MDR-TB
4 Not yet recruiting Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®-or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent subtype C gp120/MF59;   Biological: Bivalent subtype C gp120/AS01(B);   Biological: Placebo
5 Recruiting Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46/NS2/N/ΔM2-2-HindIII;   Biological: Placebo
6 Recruiting Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine;   Biological: Placebo
7 Not yet recruiting JBT-101 in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE;   Lupus
Interventions: Drug: JBT-101;   Drug: Placebo
8 Not yet recruiting Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
Condition: HIV Infections
Interventions: Drug: Dolutegravir;   Drug: Emtricitabine/tenofovir alafenamide;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
9 Recruiting Etiology of Eczema Herpeticum (EH)
Condition: Eczema Herpeticum
Intervention:
10 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
11 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
12 Recruiting Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 pLAIV;   Biological: H7N9 pIIV;   Biological: AS03 adjuvant
13 Not yet recruiting Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Condition: Influenza, Human
Interventions: Biological: Seasonal LAIV;   Biological: Placebo;   Biological: Wild-type A/California/2009-like Influenza Virus
14 Recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
15 Not yet recruiting Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis
Conditions: Tuberculosis;   HIV Infections
Intervention: Drug: Bedaquiline
16 Not yet recruiting Novel Mobile Device Application to Improve Adherence
Conditions: Pediatric Heart Transplant Recipients;   Pediatric Cardiac Transplantation;   Pediatric Heart Transplantation
Interventions: Device: TPP;   Other: Control Group
17 Recruiting Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients
Conditions: Solid Organ Transplant Recipients;   Parent(s)/Guardian of Referenced Transplant Recipients
Intervention: Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
18 Not yet recruiting Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
Condition: Influenza
Interventions: Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);   Biological: H3N2v inactivated subvirion influenza vaccine;   Biological: Placebo
19 Recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
20 Recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.